

Title Page

Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus

Wenda Guan, Ph.D.^{a,c#}, Rong Qu, M.D.^{d#}, Lihan Shen, M.D.^{e#}, Kailin Mai, M.Sc.^{a#}, Weiqi Pan, Ph.D.^{a#}, Zhengshi Lin, M.D., Ph.D.^{a#}, Liping Chen, M.Sc.^a, Ji Dong, M.D.^a, Jiawei Zhang, B.Sc.^a, Pei Feng, B.Sc.^{a,f}, Yunceng Weng, Ph.D.^a, Minfei Yu, B.Sc.^a, Peikun Guan, B.Sc.^a, Jinchao Zhou, B.Sc.^a, Chuanmeizi Tu, B.Sc.^a, Xiao Wu, M.Sc.^a, Yang Wang, Ph.D.^{a,b}, Chunguang Yang, M.Sc.^a, Yun Ling, M.D.^d, Sheng Le, M.D.^d, Yangqing Zhan, M.D.^a, Yimin Li, M.D.^a, Xiaoqing Liu, M.D.^a, Heyan Zou, B.Sc.^e, Ziqi Huang, B.Sc.^e, Hongxia Zhou, Ph.D.^e, Qiubao Wu, B.Sc.^a, Wenjie Zhang, B.Sc.^a, Jiayang He, Ph.D.^a, Teng Xu, Ph.D.^g, Nanshan Zhong, M.D.^{a,b*}, Zifeng Yang, M.D., Ph.D.^{a,b,c,f*}

Affiliations

^a National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated Hospital of Guangzhou Medical University, Guangzhou, China

^b Guangzhou Laboratory, Guangzhou, China

^c Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases, KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, China

^d Huizhou Central People's Hospital, Huizhou, China

^e Department of Critical Care Medicine, Dongguan Institute of Respiratory and Critical Care Medicine, Dongguan People's Hospital, Dongguan, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 ^f State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for
24 Applied Research in Medicine and Health, Macau University of Science and
25 Technology, Taipa, Macau SAR, China

26 ^g Vision Medicals Laboratory, Guangzhou, China

27 **Keywords:** Avian influenza A(H5N6) virus; baloxavir marboxil; viral load; sepsis;
28 cytokines

29 **Running title:** Baloxavir use in critical H5N6 patients

30 #W.G., R.Q., L.S., K.M., W.P. and Z.L. contributed equally to this work.

31 ***Corresponding authors:** N.Z. and Z.Y. contributed equally to this work.

32 Zifeng Yang

33 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
34 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
35 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
36 Guangdong, 510120, China.

37 Tel: 8620-83205181; Fax: 8620-83205181; E-mail: jeffyah@163.com

38

39 Nanshan Zhong

40 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
41 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
42 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
43 Guangdong, 510120, China.

44 Tel: 8620-83062868; Fax: 8620-83062868; E-mail: nanshan@vip.163.com

45 **Author for backup contact before publication**

46 Weiqi Pan

47 National Clinical Research Center for Respiratory Disease, State Key Laboratory of
48 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated
49 Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou,
50 Guangdong, 510120, China.

51 Tel: 8620-83205181; Fax: 8620-83205181; E-mail: panweiqi@gird.cn

52

53 **Author contributions**

54 Conceived study: Zifeng Yang, Nanshan Zhong

55 Designed study and experiments: Wenda Guan, Rong Qu, Lihan Shen, Kailin Mai, Weiqi
56 Pan, Zhengshi Lin, Zifeng Yang, Nanshan Zhong

57 Performed experiments: Wenda Guan, Rong Qu, Lihan Shen, Kailin Mai, Weiqi Pan, Liping
58 Chen, Ji Dong, Jiawei Zhang, Pei Feng, Yunceng Weng, Minfei Yu, Peikun Guan, Jinchao
59 Zhou, Chuanmeizi Tu, Xiao Wu, Chunguang Yang, Yun Ling, Sheng Le, Yangqing Zhan, Yimin
60 Li, Xiaoqing Liu, Heyan Zou, Ziqi Huang, Hongxia Zhou, Qiubao Wu, Wenjie Zhang, Jiayang
61 He, Teng Xu

62 Interpreted data: Kailin Mai, Weiqi Pan, Zhengshi Lin, Wenda Guan, Rong Qu, Lihan Shen,
63 Nanshan Zhong, Zifeng Yang

64

65 **Highlights:**

66 (1) Baloxavir potently decreased viral load in avian influenza H5N6 human infections.

67 (2) Preexisting conditions, extrapulmonary dysfunction and systemic inflammation
68 determined prognosis of H5N6 patients.

69 (3) Indicator cytokines in sputum and serum reflecting ARDS and sepsis progression
70 respectively, were identified in H5N6 patients.

71 **Abstract**

72 **Background:** Recent increase in human infections of highly pathogenic avian
73 influenza H5N6 virus and its high mortality have raised concerns.

74 **Methods:** To analyze evolution of outcomes, longitudinal clinical data and
75 specimens were collected from five patients infected with H5N6 virus after admission.

76 All patients received antiviral treatment either sequentially or in combination of
77 oseltamivir with baloxavir. Severity of illness, and viral load in sputum, urine and blood,
78 and cytokine levels in serum and sputum were serially analyzed.

79 **Results:** When delayed oseltamivir showed poor effects on high respiratory viral
80 load, baloxavir was prescribed and viral load had a rapid reduction. All patients
81 developed acute respiratory distress syndrome (ARDS) and sepsis within one week
82 after disease onset, three patients died eventually. Nonsurvivors had more severe
83 preexisting condition, extrapulmonary organ dysfunction and insufficient H5N6 virus-
84 specific antibody response. Grouped by delta SOFA on the sample collection date,
85 serum levels of IL-1 α , IL-1 β , IL-1RA, MIF, Mig, MIP-1 α , IFN- γ , IL-12p40, IL-16, IL-18,
86 IL-2R α , IL-6, basic FGF, G-CSF, HGF, M-CSF, SCF were identified as indicator
87 cytokines reflecting sepsis progression; and sputum levels of IL-18, IL-6, HGF, M-CSF
88 were indicators of ARDS progression. Comparisons of cytokine levels before, during

89 and after baloxavir treatment suggested that, baloxavir may also reduce a few
90 indicator cytokines in sputum and serum that related to viral load and multi-organ
91 dysfunction.

92 **Conclusions:** Baloxavir can effectively reduce viral load and few proinflammatory
93 cytokines associated with deterioration. However, disease outcome is determined by
94 severity of preexisting conditions and multi-organ dysfunction.

95 **Keywords:** Avian influenza A(H5N6) virus; baloxavir marboxil; viral load; sepsis;
96 cytokines

97 **An update version of this manuscript is under revision in *Med* from Cell Press.**

98

99

100

101

102

103

104

105

106

107

108

109

110

111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132

Text

Introduction

Human infection with avian influenza A viruses can cause severe diseases, in which highly pathogenic avian influenza (HPAI) A viruses often induce fulminant pneumonia and multi-organ failure. The first outbreak of zoonotic avian influenza A viruses in human occurred in Hong Kong in 1997, with 6 deaths in 18 cases resulted from highly pathogenic avian influenza (HPAI) A subtype H5N1 virus infection [1]. As of January 2023, H5N1 infections have caused at least 868 human cases with 457 deaths worldwide (case fatality rate [CFR], 52.6%) [2]. Since 2013, continued reassortment of H5N1 viruses has generated multiple subtypes [3], in which novel HPAI H5N6 viruses of clade 2.3.4.4 have recently become the dominant H5 lineage circulating in China [4]. After the first case reported in 2014, most H5N6 human infections occurred in China, except for one case reported from Laos in 2021 [5]. As of 10 March 2023, totally 84 cases and 33 deaths of H5N6 human infection were reported globally (CFR, 39.3%) [6], in which 36 cases and 22 cases arose in 2021 and 2022, respectively, and such increase of human HPAI infection seems to continue [4, 7], posing potential public health threat.

Human H5N6 infections commonly initiated with fever and cough, which were difficult to distinguish from other respiratory infection at early stage [4, 8], and subsequently acute respiratory distress syndrome (ARDS), sepsis and multiple organ dysfunction (MOD) rapidly progressed [9, 10]. High viral load, prolonged viral shedding, and the elicited intense inflammatory response are central to the pathogenesis of HPAI human

133 infections [11, 12], hence early antiviral treatment and timely immunomodulatory
134 therapy play a crucial role in clinical management. However, the longitudinal viral and
135 immunological associations with disease outcome remain unclear.

136 Neuraminidase inhibitors (NAI), usually oseltamivir monotherapy, has survival benefit
137 for H5N1 and H7N9 patients especially when treatment initiated early in the clinical
138 course [13, 14]. On the other hand, delayed NAI treatment proved to be an
139 independent risk factors of prolonged viral shedding and NAI combination therapy
140 could not reduce shedding duration in H7N9 patients [15]. Baloxavir marboxil is a novel
141 small-molecule cap-dependent endonuclease inhibitor targets influenza polymerase
142 acidic protein subunit, which has greater antiviral effects against influenza virus than
143 oseltamivir, both in mouse models and uncomplicated influenza patients [16, 17].
144 Furthermore, baloxavir exhibits better antiviral effects and protection against lethal
145 challenge compared with oseltamivir in lethal mouse models of avian influenza virus
146 H7N9 [18] and H5N1 [19]. However, the effectiveness of baloxavir against HPAI
147 human infection remains unknown.

148 Here, we reported five laboratory-confirmed human infection cases with avian H5N6
149 virus discovered in Guangdong province, China. All these patients received antiviral
150 treatment using either sequentially or in combination of oseltamivir with baloxavir. We
151 discovered indicator cytokines reflecting ARDS or sepsis progression and their
152 correlations with viral load, virus-specific serological response and disease severity
153 were analyzed. To evaluate potential effects of baloxavir, levels of indicator cytokines
154 were compared before, during, and after treatment.

155

156 **Methods**

157 *Design overview and participants*

158 Five patients with laboratory-confirmed H5N6 virus infection between August 2021 and
159 July 2022 in Guangdong Province, China, were included. As previously described,
160 infection of avian influenza A(H5N6) virus was confirmed by metagenomic next-
161 generation sequencing(mNGS) [4], reverse-transcriptase polymerase chain reaction
162 (RT-PCR) assay [20] and serologic testing of hemagglutination inhibition assay and
163 microneutralization assay [21]. Details of laboratory diagnosis are provided in the
164 Supplementary Appendix.

165 The study was approved by ethical committees of The First Affiliated Hospital of
166 Guangzhou Medical University (Ethics No. 2016-78). Written consents have been
167 signed by the patients or their family members for collecting samples and clinical data
168 for this study.

169

170 *Clinical data and sample collection*

171 Medical records of five patients were collected and reviewed by a team of physicians
172 who had clinical experience with avian influenza. Samples of different time points from
173 each H5N6 patient were collected according to actual clinical situation, in which blood,
174 throat swabs, sputum and bronchoalveolar lavage fluid (BALF) were accessible from
175 all patients, while urine samples were able to obtain from patient 1, 2, 3 and 5.

176

177 *Identification and characterization of H5N6 virus from patients' respiratory samples*

178 Details of methods used to identify and characterize the H5N6 virus were provided in
179 the Supplementary Appendix. Briefly, BALF samples from five patients were used for
180 mNGS analysis; the eight gene fragments of H5N6 virus were amplified by
181 conventional RT-PCR (Supplementary Table 1) and the PCR product was purified and
182 sequenced. The H5N6 viral load was measured on sputum, throat swabs, peripheral
183 blood and urine samples from the patients. Viral RNAs were extracted from heat
184 inactivated clinical samples using the QIAamp Viral RNA Kit (Qiagen) in a biosafety II
185 laboratory. Quantitative detection of viral nucleic acid in the above samples was then
186 performed using the Detection Kit for Influenza A virus RNA (HUARUIAN BIOLOGY)
187 and analyzed simultaneously according to the manufacturer's instruction.

188

189 *Measurements of sequential organ failure assessment score*

190 To quantify severity of organ dysfunction in H5N6 patients, admission and daily
191 maximum Sequential Organ Failure Assessment (SOFA) [22, 23] was scored and
192 reviewed by the team of experienced physicians as mentioned above. During
193 assessment, some principles [24] were followed to ensure applicability and
194 consistency, and details were provided in the Supplementary Appendix and
195 Supplementary Table 2. Sepsis was diagnosed with SOFA score above two[22]. Delta
196 SOFA score was calculated as the change of SOFA score from admission to the
197 defined time point.

198

199 *Definitions*

200 The time of disease onset was defined as the date of influenza-like illness (ILI) onset
201 (fever and cough or sore throat) or other acute-onset signs or symptoms (e.g., fatigue
202 and dyspnea) consistent with influenza illness, which was designated as day 0 after
203 onset (D0). For dynamic measurements, the time of viral load, SOFA scores, cytokines
204 and other laboratory indices were calculated from disease onset to the sample/data
205 collection date. Viral shedding duration referred to the time from disease onset to the
206 last positive result on RT-qPCR tests, in which threshold cycle values above 35 was
207 defined as negative results. Definitions of pneumonia, ARDS and acute kidney injury
208 are provided in the Supplementary Appendix.

209

210 *Antiviral treatment*

211 NAI therapy (oseltamivir) was given according to local clinical practice. Baloxavir was
212 administered when respiratory viral load remained above 5 log₁₀ copies/mL after at
213 least 4 days of NAI treatment, as 40 mg (for 40 kg to <80 kg bodyweight) or 80mg (for
214 ≥80 kg bodyweight) enterally for every 3 days and terminated when influenza viral
215 RNA was negative. Patient 1 and patient 4 received oseltamivir-baloxavir sequential
216 treatment because of severe renal failure, and other patients received oseltamivir-
217 baloxavir combined treatment (Table 1).

218

219 *Cytokine measurements*

220 Sputum and serum samples of five patients were collected at multiple time points after

221 hospitalization (Supplementary Table 3 and Supplementary Figure 1). Protein
222 concentrations of 48 cytokines in sputum supernatants and serum were measured
223 using the Bio-Plex Pro Human Cytokine Screening 48-Plex Panel on the Bio-Plex 200
224 Multiplex Testing System (Bio-Rad) following manufacturer instructions.

225

226 *Statistical analysis*

227 Correlations between cytokines, viral load and clinical parameters were assessed by
228 Spearman's correlation tests. Serum cytokines at multiple time points from five
229 patients were bulked and grouped according to delta SOFA at the corresponding time
230 points, which included delta SOFA ≥ 0 or delta SOFA < 0 . Sputum cytokines were
231 grouped by delta SOFA respiration sub-scores. Cytokine levels between groups were
232 compared and significance was determined by Wilcoxon rank-sum tests. GraphPad
233 Prism 9.0, R package corrplot (<https://cran.r-project.org/web/packages/corrplot/>) and
234 ggpubr (<https://cran.r-project.org/web/packages/ggpubr/>) were used for analysis.

235

236 **Results**

237 *Features of epidemiology, clinical manifestation and laboratory abnormalities in H5N6* 238 *virus infected patients*

239 All five patients had contact history with poultry that had no signs of HPAI infection
240 (Table 1). Patients with more severe underlying conditions (patient 1 and 4) had
241 backyard-raised chickens, and the others with less severe chronic illness worked in
242 the farmers' market. Nonsurvivors had major comorbidities of hypertension (patient 1,

243 3 and 4), diabetes (patient 1 and 4), and chronic obstructive pulmonary disease
244 (COPD, patient 4). All patients initially presented with ILI symptoms and quickly
245 developed into dyspnea and ARDS ($\text{PaO}_2/\text{FiO}_2 < 300$) within one week, requiring
246 invasive mechanical ventilation. With SOFA score above two, sepsis was diagnosed
247 in five patients on ICU admission and as hypoxemia worsened, extracorporeal
248 membrane oxygenation was administered in four patients (Figure 1A-1E and
249 Supplementary Figure 1). As fulminant pneumonia developed, influenza was firstly
250 suspected. However, with continuously searching for causative pathogens, avian
251 influenza A (H5N6) virus wasn't found in the patients' respiratory tracts until mNGS on
252 BALF (Supplementary Appendix). Phylogenetic analysis showed that the
253 hemagglutinin (HA) genes of H5N6 virus derived from all five patients belonged to
254 clade 2.3.4.4, whereas the neuraminidase genes (NA) belonged to Major clade among
255 H5N6 serotypes [25] (Supplementary Figure 2). Serological analysis further confirmed
256 the diagnosis (Figure 1F-1J).

257 Three patients required renal replacement therapy because of preexisting diabetic
258 nephropathy (patient 1) and acute kidney injury arose (patient 3 and 4). Intravenous
259 corticosteroids were prescribed in all patients, in which patient 3 and 5 were given
260 more than once. Characteristics of laboratory measurements in five patients were
261 summarized in Supplementary Table 4. Serum creatinine in patient 1, 3 and 4 elevated
262 on admission, suggesting renal dysfunction. In patient 1, 2, 3 and 5, bacterial infection
263 was confirmed by positive sputum or blood culture results after at least 10 days of viral
264 RNA detection. Three patients had bacteria cultured in sputum and multidrug-resistant

265 bacteria emerged in patient 1 and patient 5. *Staphylococcus epidermidis* septicemia
266 presented in patient 3. After at least 30 days in ICU, patient 1, 3 and 4 died from sepsis
267 and multiple organ failure, and patient 2 and 5 survived.

268 Compared with survivors, nonsurvivors (patient 1, 3 and 4) had more dysfunctional
269 organs involved, dominated by respiratory, cardiovascular and renal systems, in which
270 SOFA scores gradually increased and endured until death (Figure 1A, 1C and 1D).
271 Moreover, nonsurvivors had relatively low or delayed antibody response (Figure 1F,
272 1H and 1I).

273

274 *Antiviral effects of baloxavir treatment*

275 High viral load (above 5 log₁₀ copies/mL) was detected in sputum from all patients,
276 while viral load in throat swabs was relatively low (Figure 2). For patient 2, viral RNA
277 was detected in urine and duration of urine viral shedding was 25 days (Figure 2B).
278 The median time from disease onset to oseltamivir prescription was 5 days for five
279 patients (Table 1 and Supplementary Figure 1). Considering high sputum viral load
280 and relatively poor effects of delayed NAI usage [12], baloxavir marboxil [17, 26] was
281 prescribed. Median time from disease onset to baloxavir prescription was 11 days. In
282 4 patients (patient 1, 2, 3 and 4), median sputum viral load was above 5 log₁₀
283 copies/mL after 5 days of double-dose oseltamivir, but was enormously reduced after
284 baloxavir prescription, with over 200-fold reduction on average after twice baloxavir
285 prescriptions (Figure 2A-2D). Median viral shedding duration of all patients was 22
286 days. Patient 5 who survived, had the shortest duration of viral shedding (16 days);

287 the time from disease onset to baloxavir prescription was 7 days, which was the
288 earliest initiation of baloxavir usage among five patients (Table 1 and Figure 2E).
289 These results suggested that usage of baloxavir can potently and rapidly decrease the
290 viral load in H5N6 patient even at the later stage of disease.

291 Associations between viral dynamics with severity of hypoxemia and sepsis were
292 analyzed respectively (Supplementary Figure 3). Statistically significant correlations
293 between viral load with both PaO₂/FiO₂ ratio and SOFA scores were only found in two
294 patients, indicating that H5N6 viral load in airways may not be a sole determinant for
295 hypoxemia development and vital organ damage.

296

297 *Identification of indicator cytokines and the effect of baloxavir on their levels*

298 For further investigation on immunological response, sputum and serum samples were
299 collected from five patients to measure cytokine levels throughout their disease
300 trajectories (Supplementary Figure 4 and 5). Strong and comparable correlation
301 intensities were observed between sputum cytokines in survivors and nonsurvivors;
302 however, serum cytokines were more pronounced in nonsurvivors than in survivors
303 (Supplementary Figure 6).

304 Delta SOFA has been recommended in clinical practice [27] to dynamically evaluate
305 severity of sepsis and organ dysfunction for its reliable association with mortality and
306 low degrees of heterogeneity [24]. To discover cytokines with potential value of
307 dynamic assessment, we first classified sampling timepoints as disease progression
308 or regression by $\Delta \text{SOFA} \geq 0$ or $\Delta \text{SOFA} < 0$ (Figure 3A). Cytokines with

309 statistically significant differences between two kinds of timepoints were identified as
310 indicator cytokines, which could reflect disease status of H5N6 patients. Among 48
311 cytokines, we found 4 cytokines in sputum and 18 cytokines in serum as indicators of
312 ARDS progression and sepsis progression, respectively. Sputum IL-18, IL-6, HGF, M-
313 CSF significantly elevated when ARDS deteriorated (Figure 3B). Serum IL-1 α , IL-1 β ,
314 IL-1RA, MIF, Mig, MIP-1 α , IFN- γ , IL-12p40, IL-16, IL-18, IL-2R α , IL-6, basic FGF, G-
315 CSF, HGF, M-CSF, SCF significantly increased, Eotaxin significantly decreased when
316 sepsis deteriorated (Figure 3C).

317 Next, we analyzed correlations between indicator cytokines with days after disease
318 onset (D.A.O), viral load, serum antibody titers and SOFA scores, respectively. Levels
319 of indicator cytokines in sputum were all positively correlated with sputum viral load
320 and SOFA scores, and HGF significantly decreased over D.A.O (Figure 4A). Except
321 for IL-12p40 and G-CSF, all indicator cytokines in serum had positive correlation with
322 SOFA scores, and the majority also had positive correlations with renal sub-scores
323 (Figure 4B). Serum Mig and IL-18 were positively correlated with viral load, SOFA
324 scores and four sub-scores, while IL-18 significantly decreased over D.A.O. Besides,
325 lower titers of virus-neutralizing antibody correlated with higher IL-6 and IL-1 β levels
326 in serum. To evaluate impacts of baloxavir on indicator cytokine levels, sampling
327 timepoints were divided as before/during/after baloxavir treatment, and the alterations
328 in cytokine levels were compared. All 4 indicator cytokines in sputum significantly
329 decreased after baloxavir treatment (Figure 4C). However, only Mig and IL-18
330 statistical-significantly decreased in serum indicator cytokines after baloxavir

331 treatment (Figure 4D). The above results suggested that, indicator cytokines could
332 reflect the disease status of H5N6 patients, correlating with viral load, antibody
333 response, and MOD. Baloxavir predominantly reduced respiratory inflammatory
334 response, but also could reduce a few systemic cytokines related to MOD, which may
335 be partially attributed to its antiviral effect.

336

337 **Discussion**

338 Limited by case numbers, previous summary of H5N6 human cases focused on
339 comparisons with other influenza A virus infections [28] and lacked longitudinal data
340 regarding disease pathogenesis. Our results revealed that, patients with underlying
341 chronic illness was predisposed to H5N6 infection, which were also associated with
342 fatality in influenza A(H1N1)pdm09 [29] and avian A(H7N9) [30] infections. H5N6
343 patients suffered from rapidly progressed and refractory sepsis, a life-threatening
344 syndrome that mostly triggered by infection and characterized as systemic immune
345 chaos with multi-organ failures [31]. Bacteria is frequently associated with sepsis
346 development [32], yet viral sepsis has attracted attention for its high prevalence in
347 COVID-19 [33]. The fact that sepsis developed in all H5N6 patients without evidence
348 of bacterial infection within the first two weeks leads to a suspicion that it was triggered
349 by high viral load, since influenza A virus was mostly detected in viral pneumonia-
350 related sepsis [34]. Host immune response to influenza shares some common
351 pathways with the response to bacteria [35, 36] might be an explanation. On the other
352 hand, both seasonal and avian influenza infection were highly predisposed to bacterial

353 infection, which is the leading cause of clinical deterioration [30, 36]. Positive cultures
354 and elevated PCT revealed that, bacterial infections developed in all H5N6 patients
355 after LRT viral load decreased and augmented organ dysfunction [32]. We proposed
356 that H5N6 virus exacerbated underlying chronic illness and subsequently induced
357 MOD, leading to poor outcomes.

358 As the incidence of HPAI infections in human rises [4], the search for more effective
359 antiviral and immunomodulatory therapy becomes urgent. This is the first report of
360 baloxavir for antiviral treatment in avian influenza human infection. Consistent with
361 studies on severe influenza patients [26], baloxavir-NAI combination exhibited potent
362 antiviral effect without outcome advantage. Our results showed that baloxavir could
363 potentially decrease lung inflammation in H5N6 human infections, compatible with the
364 efficacy in H5N1 murine models [19], yet had limited influence on serum cytokines.
365 Inadequate virus-specific serological response and hypercytokinemia may account for
366 such unsatisfactory outcome, raising the possibility of using antibody-based treatment
367 and immune modulators. In our data, the patient who took baloxavir within one week
368 after illness onset had the shortest duration of viral shedding and survived, even with
369 intravenous corticosteroids prescription that could prolong viral clearance [37],
370 suggesting the coordination of potent antivirals and immune modulators has potential
371 therapeutic benefit for extreme circumstances of avian influenza human infections.

372 While most cytokines in respiratory tract decreased with time and viral load, systemic
373 inflammation dominated in H5N6 patients. Among the serum indicator cytokine profiles
374 we discovered, IL-6, M-CSF and HGF have been previously identified as markers

375 reflecting organ damage in severe COVID-19 patients [38]. Notably, taking together
376 both our results and previous comparisons of serum cytokine profiles between H5N6,
377 H7N9 and H1N1 patients [28], we speculate that serum IL-2R α , IL-12p40 and M-CSF
378 play pivotal roles in H5N6-induced sepsis and could be biomarkers of critical cases.
379 Increased concentration of serum IL-2R α is the result of T-cell activation [39], while IL-
380 12p40 mainly acts as chemoattractant and M-CSF is colony-stimulating factor both for
381 macrophages. Hypercytokinemia in H5N6 patients suggests the potential role of anti-
382 cytokine antibodies and cytokine modulators [40], such as IL-6 receptor blockade and
383 Janus kinase inhibitors [41].

384 It is also interesting to note that H5N6 virus RNA was detected in urine from one
385 survivor (patient 2), while no evidence of viremia or renal dysfunction presented. This
386 is the first report on urine viral shedding in H5N6 patients, which has been previously
387 found in human infected with influenza A(H7N9) virus [42]. No association between
388 urine viral RNA detection and renal dysfunction could be possibly accounted for
389 hematogenous dissemination through infected lymphocytes or macrophages [42, 43].
390 There are limitations in this research. Case numbers were constrained by the sporadic
391 occurrence of H5N6 human infections. As a retrospective summary of five cases,
392 influence of systemic corticosteroids on secondary bacterial infection and outcome
393 was unclear, which could also confound the cytokine profile analysis, remaining an
394 ongoing challenge. While our case study provides some insights on antiviral treatment
395 for HPAI human infections, the variability in patients and approach makes it difficult to
396 draw string conclusions and therefore highlights the need for a prospective hypothesis

397 driven study. It is interesting to investigate whether the initiation of baloxavir
398 prescription as early as possible once patients show influenza-like symptoms in an
399 HPAI endemic area, and the application of immunomodulators when hypercytokinemia
400 develops, could lower the CFR of HPAI human infections.

401 **Conclusion**

402 In summary, our study illustrates that for human infection with H5N6 virus, baloxavir
403 can effectively reduce viral load and prevent pulmonary deterioration even at the later
404 stage of disease. However, preexisting conditions, extrapulmonary dysfunction and
405 systemic inflammation are potential determinants of the disease outcomes.

406

407 **Notes**

408 **Acknowledgements.** We thank Vision Medicals Laboratory and Guangzhou
409 Huayin Medical Laboratory Center Co., Ltd. for their technical support on
410 metagenomic next-generation sequencing. Also, we would like to thank Dr. Faqiang
411 He, Dr. Zhipeng Li, Dr. Ruiyu Lu, Dr. Hanmian Liu, Dr. Yongli Wu, Dr. Zihui Zhuang,
412 and the ICU teams for taking care of the patients.

413 **Disclaimer.** The funders had no role in the study design, results, interpretation, or
414 decision to submit the manuscript for publication.

415 **Financial support.** This work was supported by the National Natural Science
416 Foundation of China (grant number 81761128014). Z.Y. received support from
417 Guangzhou Institute of Respiratory Health Open Project (funds provided by China
418 Evergrande Group, grant number 2020GIRHHMS01) and Zhongnanshan Medical

419 Foundation of Guangdong Province (grant number ZNSA-2020013). W.G. reported
420 funding from Guangzhou Science and Technology Program (grant number
421 202102100003), Open Project of State Key Laboratory of Respiratory Disease (grant
422 number SKLRD-OP-202001) and Guangdong-Hong Kong-Macao Joint Laboratory of
423 Respiratory Infectious Diseases Funding Project (grant number GHMJLRID-Z-
424 202105). W.P. received support from the National Natural Science Foundation of
425 China (grant number 31970884). L.S. and H.Z. reported funding from Guangdong
426 Basic and Applied Basic Research Foundation (grant number 2020B1515120045 and
427 2020A1515110151).

428 ***Potential conflicts of interest.*** All authors declare that they have no known
429 competing financial interests or personal relationships that could have influenced the
430 work reported in this paper.

431

432 **Reference**

- 433 1. Chan PKS. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin
434 Infect Dis **2002**; 34 Suppl 2:S58-S64.
- 435 2. World Health Organization. Cumulative number of confirmed human cases for avian
436 influenza A(H5N1) reported to WHO, 2003-2023, 5 January 2023. Available at:
437 [https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-](https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2022-5-jan-2023)
438 [avian-influenza-a\(h5n1\)-reported-to-who-2003-2022-5-jan-2023](https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2022-5-jan-2023).
- 439 3. Claes F, Morzaria SP, Donis RO. Emergence and dissemination of clade 2.3.4.4 H5Nx
440 influenza viruses-how is the Asian HPAI H5 lineage maintained. Curr Opin Virol **2016**; 16:158-

- 441 63.
- 442 4. Zhu W, Li X, Dong J, et al. Epidemiologic, Clinical, and Genetic Characteristics of Human
443 Infections with Influenza A(H5N6) Viruses, China. *Emerging Infectious Disease journal* **2022**;
444 28:1332.
- 445 5. World Health Organization Western Pacific Region. Avian influenza weekly update number
446 785, 26 March 2021. Available at: [http://apps.who.int/iris/bitstream/handle/10665/341148/AI-](http://apps.who.int/iris/bitstream/handle/10665/341148/AI-20210326.pdf?sequence=209&isAllowed=y)
447 [20210326.pdf?sequence=209&isAllowed=y](http://apps.who.int/iris/bitstream/handle/10665/341148/AI-20210326.pdf?sequence=209&isAllowed=y).
- 448 6. World Health Organization Western Pacific Region. Avian influenza weekly update number
449 886, 10 March 2023. Available at: [https://apps.who.int/iris/bitstream/handle/10665/365675/AI-](https://apps.who.int/iris/bitstream/handle/10665/365675/AI-20230310.pdf?sequence=76&isAllowed=y)
450 [20230310.pdf?sequence=76&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/365675/AI-20230310.pdf?sequence=76&isAllowed=y).
- 451 7. Chen J, Xu L, Liu T, et al. Novel Reassortant Avian Influenza A(H5N6) Virus, China, 2021.
452 *Emerg Infect Dis* **2022**; 28:1703-7.
- 453 8. Uyeki TM, Peiris M. Novel Avian Influenza A Virus Infections of Humans. *Infect Dis Clin*
454 *North Am* **2019**; 33:907-32.
- 455 9. Feng Y, Guan W, Yuan B, et al. Emergence of triple-subtype reassortants of fatal human
456 H5N6 avian influenza virus in Yunnan, China. *J Infect* **2016**; 72:753-6.
- 457 10. Yang Z-F, Mok CKP, Peiris JSM, Zhong N-S. Human Infection with a Novel Avian Influenza
458 A(H5N6) Virus. *N Engl J Med* **2015**; 373:487-9.
- 459 11. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1)
460 is associated with high viral load and hypercytokinemia. *Nat Med* **2006**; 12:1203-7.
- 461 12. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease
462 caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of

- 463 antiviral resistance. *Lancet* **2013**; 381:2273-9.
- 464 13. Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza
465 virus A subtype H5N1. *J Infect Dis* **2012**; 206:1359-66.
- 466 14. Zheng S, Tang L, Gao H, et al. Benefit of Early Initiation of Neuraminidase Inhibitor
467 Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. *Clin Infect Dis* **2018**;
468 66:1054-60.
- 469 15. Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients
470 With Avian Influenza A(H7N9) Virus Infection. *J Infect Dis* **2018**; 217:1708-17.
- 471 16. Fukao K, Noshi T, Yamamoto A, et al. Combination treatment with the cap-dependent
472 endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of
473 influenza A virus infection. *J Antimicrob Chemother* **2019**; 74:654-62.
- 474 17. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in
475 Adults and Adolescents. *N Engl J Med* **2018**; 379:913-23.
- 476 18. Taniguchi K, Ando Y, Nobori H, et al. Inhibition of avian-origin influenza A(H7N9) virus by
477 the novel cap-dependent endonuclease inhibitor baloxavir marboxil. *Sci Rep* **2019**; 9:3466.
- 478 19. Taniguchi K, Ando Y, Kobayashi M, et al. Characterization of the In Vitro and In Vivo
479 Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
480 *Viruses* **2022**; 14.
- 481 20. Heine HG, Foord AJ, Wang J, et al. Detection of highly pathogenic zoonotic influenza virus
482 H5N6 by reverse-transcriptase quantitative polymerase chain reaction. *Virology* **2015**; 12:18.
- 483 21. Department of Communicable Disease Surveillance and Response WHO. WHO manual
484 on animal influenza diagnosis and surveillance. Available at:

- 485 <https://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf>.
- 486 22. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
487 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* **2016**; 315:801-10.
- 488 23. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure
489 Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on
490 Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care*
491 *Med* **1996**; 22:707-10.
- 492 24. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and
493 challenges of accurate assessment in clinical trials. *Crit Care* **2019**; 23:374.
- 494 25. Bi Y, Chen Q, Wang Q, et al. Genesis, Evolution and Prevalence of H5N6 Avian Influenza
495 Viruses in China. *Cell Host Microbe* **2016**; 20:810-21.
- 496 26. Kumar D, Ison MG, Mira J-P, et al. Combining baloxavir marboxil with standard-of-care
497 neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a
498 randomised, parallel-group, double-blind, placebo-controlled, superiority trial. *Lancet Infect*
499 *Dis* **2022**; 22:718-30.
- 500 27. de Grooth H-J, Geenen IL, Girbes AR, Vincent J-L, Parienti J-J, Oudemans-van Straaten
501 HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and
502 meta-regression analysis. *Crit Care* **2017**; 21:38.
- 503 28. Bi Y, Tan S, Yang Y, et al. Clinical and Immunological Characteristics of Human Infections
504 With H5N6 Avian Influenza Virus. *Clin Infect Dis* **2019**; 68:1100-9.
- 505 29. Singanayagam A, Singanayagam A, Wood V, Chalmers JD. Factors associated with
506 severe illness in pandemic 2009 influenza a (H1N1) infection: implications for triage in primary

- 507 and secondary care. *J Infect* **2011**; 63:243-51.
- 508 30. Zheng S, Zou Q, Wang X, et al. Factors Associated With Fatality Due to Avian Influenza
509 A(H7N9) Infection in China. *Clin Infect Dis* **2020**; 71:128-32.
- 510 31. Gu X, Zhou F, Wang Y, Fan G, Cao B. Respiratory viral sepsis: epidemiology,
511 pathophysiology, diagnosis and treatment. *European Respiratory Review* **2020**; 29:200038.
- 512 32. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of
513 sepsis and potential therapeutic targets. *Nat Rev Immunol* **2017**; 17:407-20.
- 514 33. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus Disease 2019 as
515 Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. *Crit Care Med* **2021**; 49:2042-
516 57.
- 517 34. Cillóniz C, Dominedò C, Magdaleno D, Ferrer M, Gabarrús A, Torres A. Pure Viral Sepsis
518 Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. *J Infect*
519 *Dis* **2019**; 220:1166-71.
- 520 35. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The
521 role of microvascular permeability: A review of mechanisms and methods. *Antiviral Res* **2012**;
522 93.
- 523 36. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and
524 epidemiology. *Crit Care* **2019**; 23:258.
- 525 37. Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A
526 (H7N9) Viral Pneumonia. *Crit Care Med* **2016**; 44:e318-e28.
- 527 38. Quartuccio L, Fabris M, Sonaglia A, et al. Interleukin 6, soluble interleukin 2 receptor alpha
528 (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic

529 hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19
530 pneumonia. *Cytokine* **2021**; 140:155438.

531 39. Damoiseaux J. The IL-2 – IL-2 receptor pathway in health and disease: The role of the
532 soluble IL-2 receptor. *Clinical Immunology* **2020**; 218:108515.

533 40. Elbahesh H, Gerlach T, Saletti G, Rimmelzwaan GF. Response Modifiers: Tweaking the
534 Immune Response Against Influenza A Virus. *Front Immunol* **2019**; 10:809.

535 41. Hays L, Black M, Prunty M, et al. Could treatment with immunomodulatory agents targeting
536 IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia?
537 A systematic and narrative review. *HRB Open Research* **2022**; 5:77.

538 42. Zhu Z, Liu Y, Xu L, et al. Extra-pulmonary viral shedding in H7N9 Avian Influenza patients.
539 *J Clin Virol* **2015**; 69:30-2.

540 43. Chan MCW, Lee N, Chan PKS, et al. Seasonal influenza A virus in feces of hospitalized
541 adults. *Emerg Infect Dis* **2011**; 17:2038-42.

542

543

544

545

546

547

548

549

Table 1. Epidemiologic and clinical characteristics of human infections with avian influenza A H5N6 virus in Guangdong Province, China from 2021 to 2022

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age ranges	51-55	51-55	51-55	66-70	41-45
Sex	Female	Male	Male	Male	Female
Place of residence	Guangdong Province	Guangdong Province	Guangdong Province	Guangdong Province	Guangdong Province
Contact history with poultry	Backyard-raised chickens	Worked in a farmers' market	Worked in a farmers' market	Backyard-raised chickens	Worked in a farmers' market
Underlying conditions	Hypertension, diabetes and diabetic nephropathy	Chronic bronchitis and anterior mediastinal teratoma	Hypertension	Hypertension, diabetes, emphysema, and duodenal ulcers, pancreatic tumor	No
Long-term smoker	No	Yes	No	No	No
Duration of symptoms before hospitalization	3	5	3	4	4
Presenting symptoms	Asthenia, fever, dyspnea	Cough, fever, fatigue, dyspnea	Cough, hemoptysis, fever, headache, fatigue, dyspnea	Melena, fatigue, fever, dyspnea, jaundice	Cough, fever, dyspnea
SOFA score on ICU admission	7	11	8	4	8
Baseline serologic response (time of sample collection, titers)	D21, HAI 1:20, MN 1:20	D8, HAI 1:20, MN 1:10	D10, HAI 1:20, MN 1:20	D9, HAI 1:10, MN 1:10	D8, HAI 1:20, MN 1:40
Complications*	<small>Preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a https://doi.org/10.1101/2023.09.03.23294799; this version posted September 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.</small>				
Pulmonary	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS	Pneumonia, ARDS
Extrapulmonary	Sepsis	Sepsis	Sepsis, acute kidney injury	Sepsis, acute kidney injury	Sepsis
Advanced life support (time of initiation†, duration days)					
Invasive mechanical ventilation	D11, 42 days	D6, 36 days	D5, 75 days	D5, 31 days	D4, 177 days
ECMO	D15, 11 days	D6, 25 days	D6, 74 days	NA	D18, 43 days
Antiviral treatment (time of given†, dosage)					
Oseltamivir	D18-D27, 150 mg every 12h	D5-D31, 150mg every 12h	D5-D31, 150mg every 12h	D5-D11, 150 mg every 12h; D20-D25, 75 mg every 12h	D4-D24, 150 mg every 12h
Baloxavir	D28, D31, D34, 40 mg	D12, D15, D18, D21, D24, 40mg	D10, D13, D16, D19, 80 mg D4-D5, Methylprednisolone 40mg;	D11, D14, D17, 40 mg	D7, D10, D13, D16, 40 mg D4-D8, Methylprednisolone 40mg every 12h;
Intravenous corticosteroids (time of given†, type and dosage)	D13, Dexamethasone 5mg	D12, Dexamethasone 5mg	D15, D17, Dexamethasone 5mg; D23, D25, D27, D32, Dexamethasone 10mg	D4, Methylprednisolone 40mg	D18, Methylprednisolone 40mg; D55, Dexamethasone 5mg; D69, D77, D79, D80, Methylprednisolone 40mg
Duration of viral shedding‡ (days)	38	24	20	22	16
Duration of ICU stay (days)	50	45	75	31	189
Outcome	Succumbed	Survived	Succumbed	Succumbed	Survived

*Definitions of pneumonia, ARDS and acute kidney injury are provided in the Supplementary Appendix. Sepsis was diagnosed with SOFA score above two.

†Time points are presented as numbers of days after disease onset. The date of illness onset was identified as day 0 after disease onset (D0), and the subsequent dates were calculated successively.

‡Duration of viral shedding referred to duration days from disease onset to the last positive PCR results, in which negative results were defined as threshold cycle values above 35.

Abbreviation: ICU, intensive care units; HAI, hemagglutination inhibition assay; MN, micro-neutralization assay; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation.

555

Figure legends

556

557 **Figure 1. Figure 1. Dynamic change of SOFA scores and virus-specific serologic**
558 **response in five H5N6 patients.**

559 A-E, Area charts show the temporal variations in daily maximum SOFA scores and
560 sub-scores of five patients.

561 F-J, Hemagglutinin inhibition (HAI) and microneutralization (MN) antibody titers of
562 serum samples from patients at different time points after disease onset. HAI titers
563 (blue circle) and neutralization titers (red square) are detected via recombinant (6+2)
564 DG/H5N6-PR8 virus.

565

566 **Figure 2. Dynamic change of viral load in five H5N6 patients.**

567 A-E, Viral dynamics and antiviral treatment. Respiratory viral load at different time
568 points are marked by cross signs (throat swabs) and black asterisks (sputum). Viral
569 load in urine from patient 2 are marked by gray asterisks. Filling color of light orange
570 represents duration of oseltamivir prescription. Filling color of yellow represents
571 duration of baloxavir prescription (one dose every 3 days), with or without oseltamivir.

572 Abbreviation: OSE, oseltamivir; BAX, baloxavir.

573

574 **Figure 3. Comparison of cytokine levels during illness regression and**
575 **progression to identify indicator cytokines**

576 A, Analysis workflow of identifying indicator cytokines that potentially reflect ARDS or

577 sepsis progression. Serum samples collected at multiple time points from five patients
578 are grouped according to delta SOFA at the corresponding time points, sputum
579 samples are grouped by delta SOFA respiration sub-scores. Delta SOFA is calculated
580 by the change of SOFA scores/sub-scores from admission to the specific time point
581 (detailed methods in Supplementary Appendix). At the sample collection date, delta
582 SOFA ≥ 0 indicated disease progression, and delta SOFA < 0 indicated disease
583 regression, respectively. And sputum/serum cytokine levels were compared between
584 two kinds of disease status.

585 B, Indicator cytokines in sputum. Box and jitter plots of sputum cytokine levels at ARDS
586 regression (delta SOFA respiration sub-score on the collection date < 0 , light blue,
587 samples $n=23$) compared with those at ARDS progression (delta SOFA respiration
588 sub-score on the collection date ≥ 0 , dark blue, samples $n=45$), with raw values plotted
589 on the log₁₀ scale.

590 C, Indicator cytokines in serum. Box and jitter plots of serum cytokine levels at sepsis
591 regression (delta SOFA on the collection date < 0 , orange, samples $n=11$) compared
592 with those at sepsis progression (delta SOFA on the collection date ≥ 0 , red, samples
593 $n=25$), with raw values plotted on the log₁₀ scale.

594 Medians and interquartile ranges were presented. Dots represented individual data at
595 different time points. Significance was determined by Wilcoxon rank-sum tests. *P*
596 values: * $P<0.05$, ** $P<0.01$, *** $P<0.001$.

597 Abbreviation: ARDS, acute respiratory distress syndrome.

598

599 **Figure 4. Correlation of indicator cytokine levels with viral load, clinical**
600 **parameters and effect of baloxavir treatment**

601 A, Heatmap showing correlation of sputum indicator cytokines with days after onset,
602 sputum viral load, PaO₂/FiO₂ and SOFA scores. Significance was determined by
603 Spearman's correlation tests.

604 B, Heatmap showing correlation of serum indicator cytokines with days after onset,
605 sputum viral load, SOFA scores and sub-scores. Significance was determined by
606 Spearman's correlation tests.

607 C, Effect of baloxavir treatment on sputum indicator cytokines. Box and jitter plots of
608 indicator cytokine levels in sputum before, during and after baloxavir treatment (n=16,
609 31, 21, respectively). Significance was determined by Wilcoxon rank-sum tests.

610 D, Effect of baloxavir treatment on serum indicator cytokines. Box and jitter plots of
611 indicator cytokine levels in serum before, during and after baloxavir treatment (n=7,
612 12, 17, respectively). Significance was determined by Wilcoxon rank-sum tests.

613 *P* values: * *P*<0.05, ** *P*<0.01, *** *P*<0.001, **** *P*<0.0001.

614 Abbreviation: D.A.O, days after disease onset; BAX, baloxavir.

615

616




Figure 1. Dynamic change of SOFA scores and virus-specific serologic response in five H5N6 patients






Figure 2. Dynamic change of viral load in five H5N6 patients


A. Analysis workflow



B. Sputum cytokines



C. Serum cytokines




Delta SOFA respiration sub-score Delta SOFA respiration < 0 (n=23) Delta SOFA respiration ≥ 0 (n=45)
Delta SOFA score Delta SOFA < 0 (n=11) Delta SOFA ≥ 0 (n=25)

Figure 3. Comparison of cytokine levels during illness regression and progression to identify indicator cytokines

A. Sputum cytokines

D.A.O	Sputum Viral load	SOFA		
		PaO ₂ /FIO ₂	Score	IL-18 M-CSF IL-6 HGF
	****		****	IL-18
	**		****	M-CSF
	****		****	IL-6
**	**		****	HGF

C. Sputum cytokines



B. Serum cytokines

D.A.O	Sputum Viral load	Serum MN titer	SOFA Respiration	SOFA Coagulation	SOFA Liver	SOFA Cardiovascular	SOFA Renal	SOFA	
								Score	Score
	****			*	*	****	*	****	Mlg
*	****			**	**	**	*	**	IL-18
					*	****	****	****	IFN- γ
					*	*	****	****	IL-16
				**			**	**	IL-1RA
							**	****	M-CSF
							*	*	IL-1 β
		*		*	**		****	****	IL-6
	*	****				****	**	**	HGF
						*	****	**	IL-2R α
						*	**	**	IL-12p40
							****	****	SCF
							**	**	IL-1 α
							**	**	basic FGF
							**	*	MIF
							****	*	MIP-1 α
	*						*	*	G-CSF
			**					*	Eotaxin

D. Serum cytokines





Figure 4. Correlation of indicator cytokine levels with viral load, clinical parameters and effect of baloxavir treatment